Nerbutix (Flucloxacillin)

Flucloxacillin, the active ingredient in Nerbutix, is a penicillinase‑resistant penicillin presented as an oral dosage form for oral use. It treats infections caused by penicillinase‑producing Staphylococcus aureus and is commonly prescribed for skin, bone and respiratory tract infections in adults and children.

GNH USA supplies Nerbutix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch. Customers benefit from reliable logistics and responsive technical support throughout the supply chain.

Flucloxacillin is used to treat bacterial infections where penicillinase‑producing organisms are involved, particularly within the skin, musculoskeletal and respiratory systems.

- Skin and soft‑tissue infections: eliminates Staphylococcus aureus causing cellulitis, impetigo and wound infections. - Bone and joint infections: eradicates organisms in osteomyelitis and septic arthritis. - Respiratory tract infections: treats pneumonia and bronchitis caused by susceptible strains.

Flucloxacillin may cause a range of adverse reactions, most of which are mild and reversible, while rare events can be severe and require immediate medical attention.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting or abdominal discomfort. - Diarrhea: may be mild to moderate. - Skin rash: erythema or pruritus. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergy with airway compromise. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: life‑threatening skin detachment. - Clostridioides difficile‑associated colitis: severe diarrhea due to bacterial overgrowth.

Before prescribing flucloxacillin, clinicians should evaluate patient history and monitor specific clinical parameters to minimize risk. - Allergy assessment: confirm no known hypersensitivity to penicillins or beta‑lactams. - Liver function monitoring: check baseline enzymes and repeat if therapy exceeds two weeks. - Renal impairment caution: adjust dose in severe renal failure. - Concomitant antibiotic use: avoid simultaneous use with bacteriostatic agents that may reduce efficacy. - Pregnancy and lactation: use only if benefit outweighs potential risk, as safety data are limited. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Flucloxacillin can alter the plasma concentrations of several medicines, necessitating careful review of a patient’s medication regimen.

Major Interactions (Avoid): - Methotrexate: increased toxicity due to reduced clearance. - Warfarin: enhanced anticoagulant effect, risk of bleeding. - Oral contraceptives: reduced estrogen levels, risk of contraceptive failure.

Moderate Interactions (Monitor Closely): - Tetracyclines: antagonistic effect reducing antibacterial activity. - Probenecid: may raise flucloxacillin levels, monitor for toxicity. - Aminoglycosides: combined nephrotoxicity risk, observe renal function.